Blog

Blog

Drug Target Encyclopedia Series (34) —TIGIT

Linkedin

Release Time：

2026-03-24 14:02

 

  

TIGIT is an inhibitory immune checkpoint receptor expressed on activated T cells, NK cells, and regulatory T cells (Tregs). By interacting mainly with CD155 (PVR), TIGIT suppresses anti-tumor immunity and contributes to immune evasion in the tumor microenvironment (TME). Because of its central role in T-cell exhaustion, NK-cell dysfunction, and Treg-mediated immunosuppression, TIGIT has become one of the most closely watched next-generation immuno-oncology targets. 

TIGIT is highly relevant in:

•  Exhausted CD8+ T cells in solid tumors
•  Dysfunctional NK cells with impaired cytotoxicity
•  Immunosuppressive Tregs in the TME
•  Multiple tumor settings where the TIGIT/CD155 axis is associated with resistance to effective anti-tumor responses 

Why TIGIT matters in drug discovery

Unlike first-generation checkpoints, TIGIT sits at the intersection of adaptive and innate immunity. This makes it attractive not only for restoring exhausted T-cell activity, but also for reactivating NK-cell–mediated tumor killing. In commercial terms, TIGIT is valuable because it offers a strong rationale for combination immunotherapy, especially in patients who do not fully benefit from PD-1/PD-L1 blockade alone. 

Emerging strategies around TIGIT

  1. Anti-TIGIT monoclonal antibodies to block inhibitory signaling.
  2. PD-1 / PD-L1 combination regimens to improve response depth and durability.
  3. Fc-engineered antibodies designed to optimize immune engagement.
  4. Biomarker-driven development, including TIGIT/CD155 expression and immune-context profiling.
  5. mRNA and cell-based tools for rapid target validation, mechanism studies, and immunotherapy research workflows.

Key challenges

  1. Identifying the right patient populations
  2. Understanding when TIGIT is a true driver versus a bystander marker of exhaustion
  3. Optimizing combination partners and antibody format
  4. Translating strong biological rationale into consistent clinical benefit

🔍 Industry takeaway

TIGIT remains a high-interest membrane protein target because it connects checkpoint biology, combination strategy, and translational biomarker development. For teams working in immuno-oncology, TIGIT is not just another checkpoint — it is a strategic node for building the next wave of immune-modulating therapeutics. 

Need TIGIT tools for your research?

 

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

 

Prev

Drug Target Encyclopedia Series (35) —FGFR3

Drug Target Encyclopedia Series (33) —NCR2

Next